217 results about "Low toxicity" patented technology

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention discloses a polypeptide with a whitening effect and a preparation method and application thereof.The polypeptide is obtained from hydrolyzed protein of babylonia areolata, the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine-cysteine, and the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine. The compound can obviously inhibit the generation of melanin in cells and the activity of tyrosinase in vitro, has the characteristics of low toxicity, low irritation, good stability, safety and high efficiency, and can be applied to whitening cosmetics.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The invention belongs to the technical field of urine wastewater treatment, and particularly discloses a novel corrosion-resistant slow-release product for urine wastewater and a preparation method of the novel corrosion-resistant slow-release product. Sucrose, isomaltitol, a Kathon solution, citric acid, sorbic acid, benzoic acid and sodium benzoate are used as main raw materials to prepare a sustained-release product. The slow-release product has the effects of preventing corrosion and odor of urine. The slow-release block can effectively inhibit hydrolysis of urea in urine wastewater, and has good corrosion-resistant and odor-resistant effects; the hardness is higher, and powder is not easy to crack after long-time storage; the dissolvability is good, the toxicity is low and the environment-friendly effect is realized. The method is simple in preparation process flow, high in repeatability, low in equipment requirement, low in production cost and easy for industrial batch production.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing and treating or improving heart diseases. The plant exovesicle provided by the invention has the advantages of low toxicity, high biocompatibility, biodegradability, no induction of immunogenicity, high yield and large-scale preparation. A large number of experimental studies prove that the pseudo-ginseng external vesicles disclosed by the invention have a remarkable heart disease prevention and treatment effect. Therefore, development and application of the fresh pseudo-ginseng medicine are promoted.

The present invention relates to a lipid pre-concentrate and a method for preparing same, wherein the lipid pre-concentrate uses a biodegradable lipid having low injection force and low toxicity to delay the release rate of a drug, thereby exhibiting sustained release so that the administered drug can be continuously released for a long period of time.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention relates to the technical field of medicines, and particularly discloses application of a Xinjiang medicine mulberry extract in preparation of a medicine for treating or preventing periapical periodontitis, which is technically characterized in that the Xinjiang medicine mulberry extract is found and proved to have a remarkable inhibition effect on periapical periodontitis key pathogenic bacterium enterococcus faecalis for the first time, the minimum inhibitory concentration (MIC) is 0.604 mg / mL, and the Xinjiang medicine mulberry extract has a remarkable inhibition effect on the periapical periodontitis key pathogenic bacterium enterococcus faecalis. The minimum bactericidal concentration (MBC) is 1.875 mg / mL, and a biological membrane can be effectively inhibited and removed; in-vivo experiments of a rat periapical periodontitis model prove that the extract can remarkably reduce the number of bacteria in root canals and relieve periapical bone destruction, the curative effect is equivalent to that of calcium hydroxide, and the extract is non-toxic to main organs and high in biocompatibility. The invention provides a new candidate and a clear technical scheme for developing an efficient and low-toxicity natural plant source root canal disinfectant.

This invention provides a drug-coated balloon catheter, its preparation method, and its application, relating to the field of medical device technology. The drug-coated balloon catheter includes a balloon catheter and a drug coating disposed on the surface of the balloon catheter; the drug coating includes an active drug and an excipient; the active drug is a flavonoid. The drug-coated balloon catheter utilizes flavonoids, which combine the advantages of low toxicity and high water solubility. While reducing the toxic side effects of the drug coating, it achieves rapid release and efficient absorption of the drug. Furthermore, through a dual mechanism of anti-proliferation and anti-inflammation, it effectively solves the problems of potential toxic side effects, limited transport efficiency, and limited functionality that may exist in existing products at high dose densities.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The present invention provides a formylpiperidine compound, a preparation method and an application thereof. The general structural formula of the formylpiperidine compound is shown in formula (I), or its isomer, or its pharmaceutically acceptable salt, ester or prodrug. The formylpiperidine compound described in the present invention is a dual-target inhibitor of 5-HT reuptake and 5-HT 1A receptor, which can overcome the problems of low clinical efficacy, poor metabolic stability and poor safety of existing antidepressant drugs, and is a compound with a novel structure, high efficiency, stability and low toxicity and having an antidepressant effect.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

The invention discloses an electrochemical polishing solution for laser additive manufacturing of a tantalum material and a preparation method and process, and relates to the technical field of surface treatment of metal workpieces. According to the electrochemical polishing solution, an alcohol-salt system is adopted for electropolishing treatment, and compared with a traditional electropolishing solution, the electrochemical polishing solution has the advantages of electrochemical and chemical stability, relatively high conductivity, relatively high controllability, relatively low toxicity, low volatility, environment friendliness and the like; the electropolishing solution has the characteristics of no volatilization, no odor, low toxicity to a human body and the like by adding the inorganic solid acid formed by replacing sulfamic acid sulfuric acid hydroxyl with amino, and not only has the oxidation capacity of sulfuric acid, but also can promote dissolution and improve the material removal rate by the amino; the electrochemical polishing solution is mild in process parameter, insensitive to temperature, capable of implementing polishing at room temperature, small in corrosion to electrolysis equipment and capable of being used for a long time.

The invention belongs to the technical field of preparation of anti-inflammatory drugs, and particularly discloses a tryptanthrin derivative and a preparation method and application thereof.The structural formula of the tryptanthrin derivative is # imgabs0, R is one of R1, R2 and R3, and when R is R1, # imgabs1 # reacts with H-R1, Pd (PPh3) 2Cl, copper iodide, triethylamine and an organic solvent to prepare the tryptanthrin derivative; when R is R2, the catalyst is prepared by reacting # imgabs2 # with H-R2, Pd2 (dppf) Cl2, potassium acetate and methylbenzene; when R is R3, the PdCl (PPh3) 4 is prepared by reacting with H-R3, silver carbonate, PdCl (PPh3) 4 and acetonitrile. The tryptanthrin derivative disclosed by the invention has high biological activity and solubility and low toxicity, and has the potential of being developed into a medicine for treating ulcerative colitis.

The present invention provides a method for preparing and applying amino acid-derived carbon dot nanozymes, belonging to the field of new biomedical materials technology. The amino acid comprises one of histidine, proline, cysteine, tryptophan, aspartic acid, arginine, lysine, methionine, and phenylalanine; the mass ratio of the amino acid to citric acid monohydrate is 1:1 to 1:5. The amino acid-derived carbon dots proposed in the present invention have free radical scavenging activity and superoxide dismutase-like properties, exhibiting low toxicity and good biosafety at the cellular, nematode, and animal levels. Furthermore, the amino acid-derived carbon dot nanozymes exhibit excellent anti-inflammatory activity, downregulating cellular inflammation, reducing oxidative stress damage to nematodes, improving intestinal flora structure, increasing the richness and diversity of intestinal flora, and alleviating and treating DSS-induced ulcerative colitis in mice. The nanozymes can be further applied to the preparation of drugs for treating inflammatory bowel disease.

The invention discloses multifunctional selenium nanoparticles for treating inflammatory bowel diseases as well as a preparation method and application of the multifunctional selenium nanoparticles, and relates to the technical field of biological medicines. The multifunctional selenium nanoparticle is of a core-shell structure and comprises an inner core and an outer layer coating the inner core, the inner core is selenium nanoparticles; and the outer layer is a polydopamine shell embedded with chitosan oligosaccharide. The multifunctional selenium nanoparticles provided by the invention have good stability and dispersibility, can target intestinal inflammation parts, prolong the in-vivo time of the nanoparticles, and show strong antioxidant and anti-inflammatory activity on cell and animal levels. The whole nanoparticle is based on low toxicity and colon targeting of a natural material, is higher in safety compared with a traditional glucocorticoid / biological preparation, relieves intestinal inflammation by adjusting a redox steady state, prolonging drug action time and the like, and is expected to become a novel colitis treatment strategy with high efficiency, targeting property and safety.

The invention discloses an oral medicine composition containing olopatadine hydrochloride and a preparation method of the oral medicine composition, and relates to the technical field of pharmaceutical preparations, and the oral medicine composition is prepared from the following components in percentage by weight: 0.5-1.5% of modified olopatadine hydrochloride nanocrystals, 0.05-0.1% of xanthan gum, 0.03-0.05% of an antioxidant, 0.5-1.5% of a flavoring agent, 0.1-0.3% of olopatadine hydrochloride-containing lipidosome and 5-10% of other auxiliary materials, and the balance of purified water. The oral medicine composition is obvious in medicine effect, low in toxic and side effects, good in taste, good in controlled release and stability and high in bioavailability.

This invention belongs to the field of chemical pharmaceuticals, specifically relating to a thiazole compound, its preparation method, pharmaceutical composition, and uses. The structure of this thiazole compound is shown in Formula I, wherein R1 and R2 are independently selected from one of the following: hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl. The thiazole compound proposed in this invention can inhibit LSD1 protease activity and simultaneously possesses low toxicity, high efficiency, high selectivity, and minimal off-target effects.

The present invention relates to the technical field of veterinary drugs, and more particularly, to a composition for treating a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01-10):(0.1-20):(0.1-5), and a mixed solvent containing water and glycerin in which the main active ingredients are soluble. The composition possesses significant curative effects on fungal infections on the skin surfaces of animals, with low toxicity and low irritation.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

This disclosure is based, at least in part, on unexpected discoveries that a novel composition of a leukotoxin (LtxA) polypeptide isolated from Aggregatibatier actin omycetcmcomitans can retain stability and biological activities for an extended period of time even after the composition, is subject to a process of lyophilization, storage, reconstitution, and / or further storage, or under an accelerated condition, and that a particular range of dosage of the LtxA polypeptide and administration regimen can provide high efficacy and low toxicity in treating cancer in a patient in need thereof.

An organic sol-gel nano-composition containing three solid lipid nano-components loaded with phytochemical active ingredients is proposed. Panax notoginseng saponins are extracted from Vietnamese Panax notoginseng. Rutin is extracted from Styphnolobium japonicum in Thai Binh Province, Vietnam, and Ginkgo biloba is extracted from Ginkgo biloba trees. The composition has shown to have low toxicity and great bioavailability. In particular, the composition is effective against local myocardial ischemias and arrhythmias, improves the blood rheology, platelet circulation and antiaggregation, and thrombosis, lowers the blood lipids to a certain limit, and has good effects against atherosclerosis. The composition has an antioxidant effect of preventing free radical damages, and has an effect of enhancing capillary resistance, strengthening the vessel walls that reduces hypertension risks, which accordingly protects the cerebral nerves, prevents strokes, and is also used to recover after strokes and other hemorrhagic diseases for the enhancement effects and reconstruction of the damaged blood vessels.

The application belongs to the technical field of biology and medicine, and discloses a PROTAC compound with a carbon chain as a connecting chain, which is developed based on a PROTAC technology, and a structural general formula of the PROTAC compound is formula 1: wherein R is -(CH2) n -, and n is 3-8. The synthesized PROTAC compound is a new compound, has a TG content reducing activity in a high-fat model established by L02 and HepG2, and has a low-toxicity activity in human hepatoma cells HepG2, human normal liver cells L02 and human umbilical vein endothelial cells HUVEC compared with a warhead. The synthesized PROTAC compound is a new type of anti-non-alcoholic fatty liver disease drug with low toxicity and high efficiency. The application of the PROTAC technology is widened while developing an efficient treatment of anti-non-alcoholic fatty liver disease.

The invention discloses an anti-cancer oligopeptide designed based on threonine and analogues thereof and application of the anti-cancer oligopeptide, the anti-cancer oligopeptide is obtained by taking KLLKKLLKKLLKKKLLKW as a structural basis, replacing amino acids at different sites with hydroxyl-containing threonine or analogues thereof, and then amidating a C terminal; the structural general formula of the compound is as follows: KXmLKKLLKKLLKW-NH2, wherein X = T, pT, F, Y or pY, and p represents phosphorylation; and m is 2, 3, 6, 7, 10, 11 or 13. The anti-cancer oligopeptide has the advantages of high efficiency, low toxicity, short sequence and the like. In-vitro anti-tumor activity and toxicity experiment results show that the compound has a relatively strong killing effect on various tumor cells, and is low in hemolytic toxicity and high in therapeutic index. Serum stability experiments further show that the protein has relatively high enzymolysis stability. A scanning electron microscope experiment shows that the anti-cancer oligopeptide can quickly kill tumor cells through an effective membrane rupture mechanism. Therefore, the compound has a good application prospect in the aspects of research on novel high-efficiency low-toxicity polypeptide anti-cancer drugs, resistance to multidrug resistance and preparation of anti-cancer drugs.

The application relates to application of a piezoelectric material in preparation of a medicine for treating gout, characterized in that a medicine active ingredient of the medicine comprises the piezoelectric material, the piezoelectric material is barium titanate; the application comprises the following steps: delivering the medicine to a lesion site, applying ultrasonic stimulation to the lesion site, and exciting in-vivo active species degradation of uric acid by the medicine. The piezoelectric material has good piezoelectric catalytic performance, excellent tissue penetration ability, low toxicity and high precision, active species can be controllably excited by means of ultrasonic action at the time of gout attack, uric acid can be efficiently degraded into allantoin which is good in solubility and non-toxic, symptoms can be rapidly relieved, the piezoelectric material can be long-term resident in joints, can keep stable catalytic effect in multiple cycles, and long-term treatment of gout can be realized by single injection, and a new gout treatment scheme which is more effective and more durable is provided.